Mirae Asset Global Investments Ltd. buys $49,991,277 stake in China Biologic Products Inc (CBPO)

China Biologic Products Inc (CBPO) : Mirae Asset Global Investments Ltd. scooped up 340,304 additional shares in China Biologic Products Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 397,893 shares of China Biologic Products Inc which is valued at $49,991,277.China Biologic Products Inc makes up approximately 1.21% of Mirae Asset Global Investments Ltd.’s portfolio.

Other Hedge Funds, Including , Alliancebernstein boosted its stake in CBPO in the latest quarter, The investment management firm added 2,729 additional shares and now holds a total of 20,795 shares of China Biologic Products Inc which is valued at $2,612,684.Blackrock Advisors reduced its stake in CBPO by selling 2,540 shares or 55.53% in the most recent quarter. The Hedge Fund company now holds 2,034 shares of CBPO which is valued at $255,552. Daiwa Securities Group added CBPO to its portfolio by purchasing 500 company shares during the most recent quarter which is valued at $58,850.

China Biologic Products Inc closed down -0.38 points or -0.33% at $114.43 with 2,43,530 shares getting traded on Tuesday. Post opening the session at $115.46, the shares hit an intraday low of $114.24 and an intraday high of $116.56 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, China Biologic Products Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $1.18. The company had revenue of $91.42 million for the quarter, compared to analysts expectations of $87.58 million. The company’s revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS.

China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).

Leave a Reply

China Biologic Products Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on China Biologic Products Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.